Asimadoline Drug Asset Due Diligence Report 2026

This Asimadoline Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Asimadoline can convert its Small molecule drug profile and κ opioid receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Asimadoline (query alias: Asimadoline)
Modality / target	Small molecule drug; κ opioid receptor; κ opioid receptor agonists
Highest global status	Phase 2
Originator	Merck Serono SA
Active developers	Tioga Pharmaceuticals, Inc.

The MCP disease footprint includes Menopausal symptoms, Vasomotor symptom. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02475447	Phase 2	Completed	249	Number of participants with adverse events
JPRN-jRCT2080221823	Phase 2		240	Percentage of subjects with improvement in abdominal pain
NCT07042516	Phase 2	Recruiting	120	Safety as Assessed by Adverse Events, Clinical Laboratory Parameters, and Vital Signs

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Tioga Pharma's Asimadoline Reduces Nighttime Itching and Improves Disease-Related Quality of Life in Patients with Atopic Dermatitis

Phase 2; n=221; evaluation: Positive. Reported fields: AE = Treatment-emergent adverse events, typically mild, were similar in drug and placebo groups. ; AE = Treatment-emergent adverse events, typically mild, were similar in drug and placebo groups.

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Asimadoline on the Duration of POI in Subjects Undergoing Laparoscopic/Hand-Assisted Lap Segmental Colonic Resection Secondary to Colon Cancer, Polypectomy or Diverticulitis

Phase 2; n=35; evaluation: not stated. Reported fields: Other (Not Including Serious) Adverse Events = 10 Participants ; Other (Not Including Serious) Adverse Events = 11 Participants ; Other (Not Including Serious) Adverse Events = 14 Participants

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Asimadoline addresses Menopausal symptoms, Vasomotor symptom. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2009-09-01	Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co. Announce Agreement to Develop and Commercialize Asimadoline in Japan	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis”. The milestone feed surfaced a patent-application signal described as “Splid pharmaceutical formulations of asimadoline”. The milestone feed surfaced a patent-application signal described as “Asimadoline derivatives comprising covalently bonded acids”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO